| Patient | Phillis Wheatley |
|---|---|
| Date of birth | 2006-07-01 |
| Identifiers | MRN HR-EN015-SYN; SSN (made up) 000-15-3360 |
| Document date | 2026-10-26 |
| Author | Abena Hartley-Okonkwo, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Asthma review five weeks after an exacerbation with a cold. [S]
Miss Wheatley returns five weeks after the sick visit for asthma with a cold, when she stepped up to budesonide-formoterol as maintenance and reliever. The nurse telephoned her two days later and she was improving; she did not come for the review booked within a week, because she was very busy after her return. She never needed the standby prednisone. Her cold cleared within ten days; she now takes one inhalation twice daily and needs an extra one about once a week, and has not woken at night for three weeks. Her peak flow is 370 to 390 L/min. The screening tests from her preventive visit were negative for HIV, hepatitis C and hepatitis B surface antigen, and she has no immunity to hepatitis B. She has news she wanted to share: she now holds her own papers and her freedom, and whatever she earns from her book is her own. For now she still lives in the same house. [S]
| Element | Detail |
|---|---|
| Control | Asthma Control Test 20; extra reliever about once a week; no night waking for three weeks |
| After the exacerbation | Nurse call on day two; review within a week missed; no oral corticosteroid needed |
| Screening results | HIV, hepatitis C antibody and hepatitis B surface antigen negative; hepatitis B surface antibody negative |
| Circumstances | Now free, with her own papers and her own earnings |
| System | Result | Finding |
|---|---|---|
| Respiratory | Negative | No night waking; extra reliever about once a week |
| Ears, nose, mouth, and throat | Negative | Cold resolved; no hoarseness or thrush |
| Constitutional | Negative | Energy back; weight 47.6 kg |
| Psychiatric | Negative | Hopeful and busy; PHQ-2 0 |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Budesonide-formoterol 160/4.5 mcg inhaler as needed only (GINA track 1, step 2, anti-inflammatory reliever): one inhalation whenever needed for symptoms or before exercise in the cold, no more than 12 inhalations a day | One inhalation as needed | Respiratory tract route | 2026-02-23 to 2026-09-21 | completed | S |
| Prednisone 20 mg oral tablet, standby course for the sea journey and the summer away: two tablets (40 mg) each morning for five days, to start only as her action plan directs | 40 mg each morning for five days if the action plan directs | Oral route | 2026-04-06 to 2026-10-26 | stopped | S |
| Meclizine 25 mg oral tablet, one tablet an hour before sailing and then once daily as needed for seasickness | One tablet daily as needed at sea | Oral route | 2026-04-06 to 2026-09-21 | completed | S |
| Folic acid 0.4 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-27 | active | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-09-21 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-10-26 | Body height | 152 | cm | S |
| 2026-10-26 | Body weight | 47.6 | kg | S |
| 2026-10-26 | Body mass index (BMI) [Ratio] | 20.6 | kg/m2 | S |
| 2026-10-26 | Systolic blood pressure | 104 | mm[Hg] | S |
| 2026-10-26 | Diastolic blood pressure | 66 | mm[Hg] | S |
| 2026-10-26 | Heart rate | 74 | /min | S |
| 2026-10-26 | Respiratory rate | 14 | /min | S |
| 2026-10-26 | Body temperature | 36.5 | Cel | S |
| 2026-10-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-10-26 | Total score [ACT] | 20 | {score} | S | ||
| 2026-10-26 | FEV1 --pre bronchodilation | 2.45 | L | Lower limit of normal; predicted 2.70 L; lower limit of normal 2.17 L (GLI Global race-neutral equations) | Normal | S |
| 2026-10-26 | FEV1 measured/predicted | 91 | % | GLI Global race-neutral equations | Normal | S |
| 2026-10-26 | FEV1/FVC | 0.78 | {ratio} | Lower limit of normal for her age (GLI Global) | Normal | S |
| 2026-10-26 | Fractional concentration of exhaled nitric oxide | 24 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | Normal | S |
| 2026-10-26 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 385 | L/min | 80 percent of her personal best of 400 L/min | Normal | S |
| 2026-10-26 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
Vital signs recorded on 2026-10-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; oxygen saturation 99 percent; peak flow 385 L/min |
| Head, eyes, ears, nose, and throat | No oral thrush |
| Respiratory | Clear |
| Inhaler technique | Correct with the spacer |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness this winter, for about three months: symptoms on three or four days a week, waking with cough and a tight chest about twice a month, breathless climbing the hill streets in cold air; worse with cold wind, kitchen and fireplace smoke, and colds; called a weak chest and asthma since childhood but never tested or treated. Asthma to be confirmed with spirometry before and after bronchodilator and FeNO | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented frail, asthmatic childhood. Superseded by the diagnosis at the second visit. |
| Asthma, confirmed, mild persistent: variable airflow obstruction (FEV1/FVC 0.72, below the lower limit of normal, rising to 0.80 after bronchodilator; FEV1 2.24 L, 83 percent predicted, rising 330 mL or 15 percent); type 2 inflammation (FeNO 38 ppb, blood eosinophils 0.38 x10^3/uL, total IgE 165, house dust mite sensitization); tuberculosis infection test negative and chest X-ray clear. Triggers: cold air, kitchen and fireplace smoke, colds | active | confirmed | J45.30 | S — Synthetic modern confirmation linked to her documented frail, asthmatic childhood and her own later descriptions of asthma. |
| Asthma exacerbation with a cold a week after returning from abroad: three days of wheeze, chest tightness and waking at night despite six to eight reliever inhalations a day; peak flow 270 L/min (68 percent of her best of 400), oxygen saturation 96 percent; 330 L/min after treatment in clinic; treated without oral corticosteroids; resolved | resolved | confirmed | J45.31 | S — Synthetic exacerbation anchored to her own letter describing a cold and asthma after her return; the clinical details are synthetic. |
| Prone to seasickness on boat trips; meclizine for the sea crossing; resolved on her return | resolved | confirmed | T75.3XXA | S — Synthetic travel-related problem. |
| Pregnancy planning: not sexually active and no contraception wanted now; she may wish to have children one day; folic acid by her choice, and asthma care planned before and during any pregnancy | active | confirmed | Z31.69 | S — Synthetic reproductive health counselling; not a claim about her real life. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 20; extra reliever about once a week; no night waking |
| Imaging | Spirometry and FeNO | Three to six months after starting treatment and after an exacerbation | Completed today | FEV1 2.45 L (91 percent); FEV1/FVC 0.78; FeNO 24 ppb |
| Imaging | Peak flow | Every visit and at home | Completed today | 385 L/min, green zone |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Correct with the spacer; maintenance doses taken by the dose counter |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Updated for maintenance and reliever through the winter |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | One exacerbation in the past year, with a cold, managed without an oral corticosteroid or emergency care |
| Self-management | Review within a week of an exacerbation | Within one to seven days after any exacerbation | Deferred | Missed: the nurse telephoned on day two, but she did not attend the review booked within a week because she was busy after her return. No harm resulted: she recovered without an oral corticosteroid and her lung function is normal today. Corrective action: the clinic now offers a telephone or video review on the fifth to seventh day when an in-person visit is not kept, and she agreed to that for any future exacerbation |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | Stepped to step 3 maintenance and reliever after the exacerbation; continue through the winter; step-down in the spring |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Colds and cold, damp air; kitchen fan and open window; no smoke exposure |
| Survey | Depression screen | Yearly and when circumstances change | Completed today | PHQ-2 0 |
| Self-management | Vaccinations | Yearly | Completed today | Influenza and COVID-19 for the new season; hepatitis B series completed; HPV dose 2 of 3 |
| Referral | Biologic assessment | When asthma is severe or uncontrolled despite optimized step 4 to 5 treatment | Not indicated | Mild asthma controlled at step 3 |
| Self-management | Private conversation: consent, safety and exploitation, and her own decisions | Every visit | Completed today | Seen alone; she reports her freedom; social work booked at her request |
Goal progress:
Immunizations given today: Hepatitis B vaccine (HepB-CpG), dose 2 of 2; Human papillomavirus vaccine (9-valent), dose 2 of 3; Influenza vaccine, the new season; COVID-19 mRNA vaccine, the new season's formula [S]
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma monograph (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Adult Immunization Schedule by Age (2026)
Follow-up: Asthma review in three months, sooner in the yellow zone. HPV dose 3 in about three months. Social work appointment next week. Preventive visit in the spring. [S]